It has just been announced that the OptiBiotix Health (OPTI) shareholding in SkinBioTherapeutics (SBTX) has been reduced to 24,940,639 – representing a move from a 13.52% interest to 12.94%. With the share price of SkinBioTherapeutics down from above 15p at the start of 2024 to now below 8p, is this a panicked sale at a low-point? We understand NOT!
This contract should not be a complete surprise as it was alluded to in the recent Steve O’Hara & Tom Winnifrith video HERE. At that point O’Hara was 90% sure it would be signed. Now it has. It is amazing that shares in Optibiotix (OPTI) are not racing ahead on this news. They should be. At 24.75p they are a STRONG BUY.
Sadly, the world is populated by fools. Gone are the days when even university students learned from primary sources rather than from what they copied from the internet. As for the chat room gerbils, here is a gem on Optibiotix (OPTI) from ADVFN:
OptiBiotix Health (OPTI) has issued a “Strategic and commercial update” announcement. There are various positives in the long-winded announcement and the shares have currently responded more than 11% higher to 25p, but that’s still below levels of even early this month and we’d have preferred a much more to-the-point announcement of financials and orders news. However, having spoken to CEO Stephen O’Hara, we believe significant progress is being made on those to mean significant potential from the current £22.8 million market capitalisation.
I am all for really kicking the tyres of a company which you are investing in or shorting. Lucian did his waistline no favours heading off to sample the heart attack inducing cakes of Cake Box (CBOX) but it was worth it in the name of research. But sometimes the personal experience can be misleading.
OptiBiotix Health (OPTI) has issued a “SweetBiotix Update” announcement. It is a, non-regulatory, RNS Reach, immediately signalling no commercial deal yet, but there are clear signs of progress towards material deals. So what of the shares currently up at 29p in response?
OptiBiotix Health (OPTI) has announced a forthcoming launch of ‘LeanBiome in Muscletech’, “one of the leading sports nutrition brands in the industry and backed by America's No. 1 selling sports supplement company”. This is good news not discounted in a current 25.5p share price, £23.3 million market capitalisation. Tom Winnifrith reckons the shares could hit 100p and explains why HERE. This site is a bit more cautious.
OptiBiotix Health (OPTI) has announced it has appointed Graham Myers as part-time Finance Director “to support the focus on driving each business unit and the group to profitability”. With it also added that “the appointment reflects the progress we have made in 2023 after a difficult 2022”, we look for the prospective trading news to boost the shares from a current 26.25p, below £24 million market capitalisation. Having an FD is part of growing up as a company and we welcome this big time.
OptiBiotix Health (OPTI) has issued a “Commercial update” announcement including that it is “seeing sales with existing partners improve month on month” and “strong” big new customers progress.
OptiBiotix Health (OPTI) has announced a license agreement to incorporate Tata Chemicals’ proprietary short chain fructo-oligosaccharide Fossenceinto its SlimBiome and LeanBiome for the Indian market.
Mr Market has looked in the rear view mirror at the results from OptiBiotix Health (OPTI), but look ahead and the shares look to be a buy big time as the company reiterates its plans for each business unit to, at least on a monthly basis, reach profitability by the end of the calendar year and that it is confident for much further growth.
OptiBiotix Health (OPTI) has issued a “Commercial update” announcement, noting commercial progress of its first-generation products range and reiterating plans for each business unit to reach operational profitability by the end of this year. What of this with the shares currently responding up towards 30p?
